Trial · NCT01782326
Results by group70
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 70
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Rate of COPD Exacerbations | QVA149 | 3.59 | 95% Confidence Interval 3.28 to 3.94 | COPD Exacerbations/year | |
| Rate of COPD Exacerbations | Long Acting B2 Agonist (LABA) and Inhaled Corticosteroid (ICS) | 4.03 | 95% Confidence Interval 3.68 to 4.41 | COPD Exacerbations/year | |
| Time to First COPD Exacerbation. | QVA149 | 71.0 | 95% Confidence Interval 60.0 to 82.0 | Days | |
| Time to First COPD Exacerbation. | Long Acting B2 Agonist (LABA) and Inhaled Corticosteroid (ICS) | 51.0 | 95% Confidence Interval 46.0 to 57.0 | Days | |
| Rate of Moderate to Severe COPD Exacerbations. | QVA149 | 0.98 | 95% Confidence Interval 0.88 to 1.10 | COPD Exacerbation/year | |
| Rate of Moderate to Severe COPD Exacerbations. | Long Acting B2 Agonist (LABA) and Inhaled Corticosteroid (ICS) | 1.19 | 95% Confidence Interval 1.07 to 1.32 | COPD Exacerbation/year | |
| Time to First Moderate to Severe COPD Exacerbation. | QVA149 | NA | 95% Confidence Interval NA to NA | Days | |
| Time to First Moderate to Severe COPD Exacerbation. | Long Acting B2 Agonist (LABA) and Inhaled Corticosteroid (ICS) | 308.0 | 95% Confidence Interval 283.0 to 352.0 | Days | |
| Rate of Moderate to Severe COPD Exacerbations Requiring Treatment With Systemic Corticosteroids | QVA149 | 0.18 | 95% Confidence Interval 0.14 to 0.22 | COPD Exacerbation/year | |
| Rate of Moderate to Severe COPD Exacerbations Requiring Treatment With Systemic Corticosteroids | Long Acting B2 Agonist (LABA) and Inhaled Corticosteroid (ICS) | 0.18 | 95% Confidence Interval 0.14 to 0.23 | COPD Exacerbation/year | |
| Rate of Moderate to Severe COPD Exacerbations Requiring Treatment With Antibiotics | QVA149 | 0.17 | 95% Confidence Interval 0.13 to 0.22 | COPD Exacerbation/year | |
| Rate of Moderate to Severe COPD Exacerbations Requiring Treatment With Antibiotics | Long Acting B2 Agonist (LABA) and Inhaled Corticosteroid (ICS) | 0.22 | 95% Confidence Interval 0.17 to 0.28 | COPD Exacerbation/year | |
| Rate of Moderate to Severe COPD Exacerbations Requiring Hospitalization. COPD Exacerbations Starting Between First Dose and One Day After Last Treatment Are Included. | QVA149 | 0.15 | 95% Confidence Interval 0.11 to 0.19 | COPD Exacerbation/year | |
| Rate of Moderate to Severe COPD Exacerbations Requiring Hospitalization. COPD Exacerbations Starting Between First Dose and One Day After Last Treatment Are Included. | Long Acting B2 Agonist (LABA) and Inhaled Corticosteroid (ICS) | 0.17 | 95% Confidence Interval 0.13 to 0.22 | COPD Exacerbation/year | |
| Rate of Moderate to Severe COPD Exacerbations Requiring Re-hospitalization Within 30 Days | QVA149 | 0.0 | Standard Deviation 0.15 | COPD Exacerbation/year | |
| Rate of Moderate to Severe COPD Exacerbations Requiring Re-hospitalization Within 30 Days | Long Acting B2 Agonist (LABA) and Inhaled Corticosteroid (ICS) | 0.0 | Standard Deviation 0.12 | COPD Exacerbation/year | |
| Time to First Moderate to Severe COPD Exacerbations Requiring Treatment With Systemic Corticosteroids | QVA149 | NA | 95% Confidence Interval NA to NA | Days | |
| Time to First Moderate to Severe COPD Exacerbations Requiring Treatment With Systemic Corticosteroids | Long Acting B2 Agonist (LABA) and Inhaled Corticosteroid (ICS) | NA | 95% Confidence Interval NA to NA | Days | |
| Time to First Moderate to Severe COPD Exacerbations Requiring Treatment With Antibiotics | QVA149 | NA | 95% Confidence Interval NA to NA | Days | |
| Time to First Moderate to Severe COPD Exacerbations Requiring Treatment With Antibiotics | Long Acting B2 Agonist (LABA) and Inhaled Corticosteroid (ICS) | NA | 95% Confidence Interval NA to NA | Days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01782326/results